Calliditas Therapeutics AB announced that the United States Patent and Trademark Office issued patent no. 11896719, entitled "New Pharmaceutical Compositions, on January 24, 2024 with validity as of February 13, 2024. This is Calliditas' second patent for TARPEYO in the United States, and provides product protection until 2043.

The patent covers a method of treating IgA nephropathy with a composition that encompasses TARPEYO® (budesonide) delayed release capsules, developed under the name "NEFECON®". Filing for listing in the Orange Book has thus been made. Calliditas intends to file corresponding patent applications in additional territories around the world, including Europe and China.